
About Pentavalent
Pentavalent is a Healthcare company based in Bengaluru (India) founded in 2015 by Bhavani PV and Soumya Paul. Vaccines and research services for infectious diseases are provided. Pentavalent has raised $40.82 thousand across 2 funding rounds from investors including Bioinnovation Centre and Startup Karnataka. Pentavalent was last valued at $806.3 thousand in October 2020. Its Indian entity Pentavalent Bio Sciences Private Limited reported revenue of βΉ2.01 Cr. Pentavalent offers products and services including Antibodies, Antigens, Cytokines, and Enzymes. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Prophylactic.
Company details
Pentavalent was founded in 2015 in Bengaluru, India, within the biotechnology sector. Research services are delivered in proteomics, genomics, molecular techniques, antibody generation, microbial studies, cell culture, computational assistance, and preclinical areas. Vaccines and diagnostics for infectious diseases are developed as part of core operations.
- Headquarters Bengaluru, India
- Founders Bhavani PV, Soumya Paul
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website pentavalent.in
- Social LinkedIn
- Legal Name Pentavalent Bio Sciences Private Limited
- Date of Incorporation 24 Feb, 2015
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹2.01 Cr
FY 2023 · +356% YoY
- Net Profit₹17.2 Lakh
FY 2023 · 9% margin
- EBITDA₹25.8 Lakh
FY 2023 · 13% margin
- Total Equity Funding$40.82K (USD)
in 2 rounds
- Latest Funding Round$40.82K (USD), Seed
Oct 2020
- InvestorsBioinnovation Centre
& 1 more
Associated legal entities of Pentavalent
Pentavalent operates through Pentavalent Bio Sciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Pentavalent Bio Sciences Private Limited CIN U85110KA2015PTC078991 | Active | 24 Feb 2015 | Bangalore, Karnataka | ₹2.0 Cr | 2 | View details |
Products & Services of Pentavalent
Pentavalent offers a comprehensive portfolio of products and services, including Antibodies, Antigens, Cytokines, and Enzymes.
Monoclonal antibodies for precise IVD testing applications
Recombinant proteins tailored for diagnostics and research
Signaling proteins for immune response diagnostics
Purified enzymes for IVD and health applications
Funding Insights of Pentavalent
Pentavalent has successfully raised a total of $40.82K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $40.82 thousand completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40,819
- Total Rounds 2
- Last Round Seed β $40,819
- First Round $77,200
(May 2017)
- Investors Count 2
All 2 funding rounds of Pentavalent with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2020 | $40,819 | Seed | $806,301 | Bioinnovation Centre | β |
| May 2017 | $77,200 | Grant | β | β |
Last known valuation $806,301 (Oct 2020). 2 investors in total: 2 institutional.
Investors in Pentavalent
Pentavalent has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bioinnovation Centre and Startup Karnataka.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Govt backed startup incubator focused on the Life Science sector | 2015 | bioinnovationcentre.com | Bengaluru, India | |
Support for startups in Karnataka is delivered through policies, funding, and networking services. | 2004 | missionstartupkarnataka.org | Bengaluru, India |
Investor details for Pentavalent
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Pentavalent Bio Sciences Private Limited (Pentavalent)
Pentavalent Bio Sciences Private Limited is the primary company behind Pentavalent. The board of Pentavalent Bio Sciences Private Limited currently have 2 directors; the longest-serving is Soumya Paul, appointed in 2015. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Soumya Paul DIN 07070580 | Director | 24 Feb 2015 | 11 yrs 8 mo | Pentavalent Bio Sciences Private Limited |
| Murali Shripathy Harishchandra DIN 07396173 | Director | 04 Dec 2015 | 10 yrs 11 mo | Pentavalent Bio Sciences Private Limited |
People of Pentavalent
2 people are tracked at Pentavalent (2 in leadership).
| Name | Role | Group |
|---|---|---|
Bhavani PV | Co-Founder & Director | Leadership |
| Co-Founder & Director | Leadership |
Complete people profiles for Pentavalent
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Pentavalent
Figures of Pentavalent Bio Sciences Private Limited, the primary company behind Pentavalent, for FY 2023. Revenue was ₹2.01 Cr (+356% year on year). Net profit was ₹17.2 Lakh (9% margin). EBITDA was ₹25.8 Lakh (13% margin). Revenue has grown at a compounded annual rate of +88% over three years and +49% over five years.
- ₹2.01 CrRevenue · FY 2023 · +356% YoY
- ₹17.2 LakhNet profit · 9% margin
- ₹25.8 LakhEBITDA · 13% margin
- ₹18.1 LakhPaid-up capital
- +88%Revenue CAGR, 3 years
- +49%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Pentavalent Bio Sciences Private Limited are on its company page.
Detailed financial statements for Pentavalent
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Pentavalent
3 dated milestones of Pentavalent across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Pentavalent is founded.
- Funding First funding round of $77K.
- Funding Latest funding round, Seed, of $41K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pentavalent
Pentavalent was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Pentavalent is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Pentavalent is a funded company, having raised a total of $40.82K across 2 funding rounds to date. The company's 1st funding round was a Grant of $77.2K, raised on May 2017.
The primary company behind Pentavalent, Pentavalent Bio Sciences Private Limited, reported revenue of βΉ2.01 Cr for FY 2023, up 356% year on year.
Pentavalent was founded in 2015 in Bengaluru, India, within the biotechnology sector. Research services are delivered in proteomics, genomics, molecular techniques, antibody generation, microbial studies, cell culture, computational assistance, and preclinical areas. Vaccines and diagnostics for infectious diseases are developed as part of core operations.
Pentavalent offers Antibodies, Antigens, Cytokines, and Enzymes.
Pentavalent has 2 investors. Key investors include Bioinnovation Centre, and Startup Karnataka.
The valuation of Pentavalent is $806.3K as of Oct 2020.
Pentavalent operates through Pentavalent Bio Sciences Private Limited.
The legal entities of Pentavalent currently have 2 directors, including Soumya Paul, Murali Shripathy Harishchandra.